The Archives of Bone and Joint Surgery

The Archives of Bone and Joint Surgery

Multifocal Osteosarcoma: Practical Insights for Orthopedic Surgeons

Document Type : SCOPING REVIEW

Authors
Khodamorad Jamshidi 1
Alireza Mirzaei 2
Shahabaldin Beheshti Fard 1
Edward Y. Cheng 3
1 Bone and Joint Reconstruction Research Center, Department of Orthopedics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 Bone and Joint Reconstruction Research Center, Department of Orthopedics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran - Department of Orthopedic Surgery, University of Minnesota, Minneapolis, Minnesota, USA
3 Department of Orthopedic Surgery, University of Minnesota, Minneapolis, Minnesota, USA
10.22038/abjs.2026.93604.4226
Abstract
Objectives: Multifocal osteosarcoma (MFOS) is an aggressive presentation of osteosarcoma characterized by multiple skeletal lesions without visceral metastasis. Despite decades of clinical recognition, its biological basis, classification, and optimal management remain poorly defined, particularly regarding distinctions between synchronous and metachronous disease. Synchronous and metachronous MFOS differ in pathogenesis, imaging characteristics, clinical behavior, treatment feasibility, and prognosis.
Methods: A narrative review of the literature was conducted using PubMed, Scopus, and Google Scholar. Studies addressing the definition, classification systems, pathogenesis, imaging characteristics, treatment approaches, and outcomes of MFOS were identified and synthesized, with particular emphasis on differences between synchronous and metachronous forms.
Results: MFOS accounts for approximately 1.5% of osteosarcoma cases. Synchronous MFOS typically presents with widespread sclerotic lesions, limited surgical options, and poor survival. In contrast, metachronous MFOS more closely resembles conventional osteosarcoma, is more often amenable to surgical resection, and demonstrates comparatively improved outcomes. Genetic predisposition syndromes and microenvironmental factors appear to play contributory roles in selected cases. However, no definitive molecular markers currently exist to distinguish true multicentric disease from early skeletal metastasis.
Conclusion: MFOS remains a diagnostically and therapeutically challenging condition with distinct clinical and prognostic differences between synchronous and metachronous forms. Improved molecular characterization and collaborative research efforts are needed to refine classification, guide treatment strategies, and improve outcomes in this rare and aggressive disease.
Level of evidence: V
Keywords
Metachronous
Multifocal osteosarcoma
Synchronous
Subjects
1.    Rahmanian M, Khoropanah S, Hosseinzadeh Moghaddam S, et al. A Systematic Review and Meta-Analysis of Regorafenib's Effectiveness and Safety in the Treatment of Bone Sarcoma. Arch Bone Jt Surg. 2025;13(12):776-787. doi: 10.22038/ABJS.2025.87671.3969.
2.    Jamshidi K, Bahrabadi M, Mirzaei A. Long-term Results of Osteoarticular Allograft Reconstruction in Children with Distal Femoral Bone Tumors. Arch Bone Jt Surg. 2017;5(5):296-301.
3.    Jamshidi K, Hajialiloo Sami S, Naghizadeh H, Kargar Shooroki K, Ahmadi R, Seyyed Khabiri S. Osteosarcoma Management in the Precision Medicine Era: Bibliometric Analysis and Clinical Progress (2015-2024). Arch Bone Jt Surg. 2025;13(11):693-703. doi: 10.22038/ABJS.2025.87193.3953.
4.    Jamshidi K, Haji Agha Bozorgi M, Mokhtari E, Bagherifard A, Mirzaei A. Scapular Osteosarcoma Treated by Scapulectomy with or Without Scapular Allograft: A Retrospective Case Series. Indian J Orthop. 2023;57(3):453-460. doi:10.1007/s43465-022-00813-2.
5.    Jamshidi K, Zandrahimi F, Bagherifard A, Mohammadi F, Mirzaei A. An unusual presentation of osteosarcoma in the proximal femur with peculiar diagnostic characteristics: a retrospective series. Curr Orthop Pract. 2021;32(4).doi: 10.1097/BCO.0000000000001016.
6.    Jenkin R, Allt W, Fitzpatrick P. Osteosarcoma. An assessment of management with particular reference to primary irradiation and selective delayed amputation. Cancer. 1972;30(2):393-400.
7.    Corradi D, Wenger DE, Bertoni F, et al. Multicentric osteosarcoma: clinicopathologic and radiographic study of 56 cases. Am J Clin Pathol.2011;136(5):799-807. doi: 10.1309/AJCP0V0OATKCNAZP.
8.    Lee HJ, Kim IO, Kim WS, Cheon JE, Kim KW, Yeon KM. Metachronous multifocal osteosarcoma: A case report and literature review. Clin Imag. 2002;26(1):63-68. doi: 10.1016/s0899-7071(01)00354-0.
9.    Odri GA, Tchicaya-Bouanga J, Yoon DJY, Modrowski D. Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers. Cancers (Basel). 2022;14(2):360.doi:10.3390/cancers14020360.
10.  Gambera S, Abarrategi A, González-Camacho F, et al. Clonal dynamics in osteosarcoma defined by RGB marking. Nat Commun. 2018;9(1):3994. doi:10.1038/s41467-018-06401-z.
11.  Wang D, Niu X, Wang Z, et al. Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. Cancer Res. 2019;79(1):7-20. doi:10.1158/0008-5472.Can-18-1086.
12.  Xu H, Zhu X, Bao H, et al. Genetic and clonal dissection of osteosarcoma progression and lung metastasis. Int J Cancer. 2018;143(5):1134-1142. doi:10.1002/ijc.31389.
13.  Enneking WF, Kagan A. "Skip" metastases in osteosarcoma. Cancer. 1975;36(6):2192-205. doi:10.1002/cncr.2820360937.
14.  Enneking WF, Kagan A. The implications of "skip" metastases in osteosarcoma. Clin Orthop Relat Res. 1975;(111):33-41. doi:10.1097/00003086-197509000-00005.
15.  Amstutz HC. Multiple osteogenic sarcomata—metastatic or multicentric? Report of two cases and review of literature. Cancer. 1969;24(5):923-931. doi: 10.1002/1097-0142(196911)24:5<923::aid-cncr2820240509>3.0.co;2-e.
16.  Mahoney JP, Spanier SS, Morris JL. Multifocal osteosarcoma. A case report with review of the literature. Cancer. 1979;44(5):1897-1907. doi: 10.1002/1097-0142(197911)44:5<1897::aid-cncr2820440552>3.0.co;2-2.
17.  Gambera S, Abarrategi A, González-Camacho F, et al. Clonal dynamics in osteosarcoma defined by RGB marking. Nature Communications. 2018;9(1):3994. doi:10.1038/s41467-018-06401-z.
18.  Brady SW, Ma X, Bahrami A, et al. The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. Mol Cancer Res. 2019;17(4):895-906. doi:10.1158/1541-7786.Mcr-18-0620.
 
19.  Muff R, Rath P, Ram Kumar RM, et al. Genomic instability of osteosarcoma cell lines in culture: impact on the prediction of metastasis relevant genes. PLoS One. 2015;10(5):e0125611. doi:10.1371/journal.pone.0125611.
20.  Connolly EA, Boye K, Bonvalot S, et al. Genetic predisposition in sarcomas: clinical implications and management. eClin Med. 2025;83doi:10.1016/j.eclinm.2025.103203.
21.  Hameed M, Mandelker D. Tumor Syndromes Predisposing to Osteosarcoma. Adv Anat Pathol. 2018;25(4):217-222. doi:10.1097/pap.0000000000000190.
22.  Saucier E, Bougeard G, Gomez‐Mascard A, et al. Li–Fraumeni‐associated osteosarcomas: The French experience. Pediatr Blood Cancer. 2024;71(12):e31362. doi: 10.1002/pbc.31362.
23.  Brandal P, Bjerkehagen B, Bruland ØS, Skjeldal S, Bogsrud TV, Hall KS. Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience. Acta Oncol. 2009;48(8):1165-1172. doi: 10.3109/02841860903032809.
24.  Zils K, Wirth T, Loff S, Biskup S, von Kalle T, Bielack S. Multiple metachronous osteosarcomas in a patient with Li-Fraumeni syndrome. Pediatr Hematol Oncol. 2014;31(4):359-361. doi:10.3109/08880018.2013.848388.
25.  Huby M, Brugières L, Mascard E, Gaspar N, Pannier S, Aurégan J-C. Difficulties of Management of Multiple Synchronous Bone Tumors in Li‐Fraumeni Syndrome. Case Rep Orthop. 2019;2019(1):8732089. doi:10.1155/2019/8732089.
26.  Pratt CB, Michalkiewicz E, Rao BN, Lipson M, Cain A, Kaste S. Multifocal osteosarcoma following retinoblastoma. Ophthal Gen. 1999;20(1):23-29. doi:10.1076/opge.20.1.23.2296.
27.  Potepan P, Luksch R, Sozzi G, et al. Multifocal osteosarcoma as second tumor after childhood retinoblastoma. Skelet Radiol. 1999;28(7):415-421. doi: 10.1007/s002560050540.
28.  Bielack SS, Baumhoer D, Hecker-Nolting S, et al. Osteosarcomas in retinoblastoma-survivors. A report of 28 affected patients from the cooperative osteosarcoma study group (COSS). EJC Paediatr Oncol. 2024;3.
29.  Zils K, Klingebiel T, Behnisch W, et al. Osteosarcoma in patients with Rothmund–Thomson syndrome. Pediatr Hematol Oncol.2015;32(1):32-40. doi: 10.3109/08880018.2014.987939.
30.  Anbari KK, Ierardi-Curto LA, Silber JS, et al. Two primary osteosarcomas in a patient with Rothmund-Thomson syndrome. Clin Orthop Relat Res (1976-2007). 2000;378:213-223. doi:10.1097/00003086-200009000-00032.
31.  Deyrup AT, Montag AG, Inwards CY, Xu Z, Swee RG, Krishnan Unni K. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med. 2007;131(6):942-946. doi:10.5858/2007-131-942-SAIPDO.
32.  Huvos AG, Butler A, Bretsky SS. Osteogenic sarcoma associated with Paget's disease of bone. A clinicopathologic study of 65 patients. Cancer. 1983;52(8):1489-1495. doi: 10.1002/1097-0142(19831015)52:8<1489::aid-cncr2820520826>3.0.co;2-x.
33.  Sivrioglu AK, Aribal S, Onder H. Secondary multifocal osteosarcoma developing on the background of bone infarct. Case Rep. 2017;bcr-2017-220293. doi:10.1136/bcr-2017-220293.
34.  Daffner RH, Kennedy SL, Fox KR, Crowley JJ, Sauser DD, Cooperstein LA. Synchronous multicentric osteosarcoma: the case for metastases. Skeletal Radiol. 1997;26(10):569-78. doi:10.1007/s002560050289.
35.  Parham DM, Pratt CB, Parvey LS, Webber BL, Champion J. Childhood multifocal osteosarcoma. Clinicopathologic and radiologic correlates. Cancer. 1985;55(11):2653-2658. doi: 10.1002/1097-0142(19850601)55:11<2653::aid-cncr2820551121>3.0.co;2-a.
36.  Setiawati R, Lay ES, Testini V, et al. Advance MR evaluation of synchronous multifocal osteosarcoma with pathologic fracture. BJR case Rep. 2021;7(4):20210015.doi:10.1259/bjrcr.20210015.
37.  Jaffe N, Pearson P, Yasko AW, Lin P, Herzog C, Raymond K. Single and multiple metachronous osteosarcoma tumors after therapy. Cancer.2003;98(11):2457-2466. doi: 10.1002/cncr.11800.
38.  Mettmann VL, Blattmann C, Friedel G, et al. Primary Multi-Systemic Metastases in Osteosarcoma: Presentation, Treatment, and Survival of 83 Patients of the Cooperative Osteosarcoma Study Group. Cancers (Basel). 2024;16(2):275.doi:10.3390/cancers16020275.
39.  Bacci G, Fabbri N, Balladelli A, Forni C, Palmerini E, Picci P. Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients. J Bone Joint Surg Br. 2006;88(8):1071-1075. doi: 10.1302/0301-620X.88B8.17809.
40.  Singh I, Rainusso N, Kurenbekova L, et al. Intrinsic Epigenetic State of Primary Osteosarcoma Drives Metastasis. Mol Cancer Res. 2024;22(9):864-878. doi:10.1158/1541-7786.Mcr-23-0055.
41.  Morrow JJ, Khanna C. Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Crit Rev Oncog. 2015;20(3-4):173-97.doi:10.1615/critrevoncog.2015013713.
42.  Moriarity BS, Otto GM, Rahrmann EP, et al. A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet. 2015;47(6):615-624. doi:10.1038/ng.3293.
43.  Sirikaew N, Pruksakorn D, Chaiyawat P, Chutipongtanate S. Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction. Int J Mol Sci. 2022;23(17):9741.doi:10.3390/ijms23179741.
 
 
The Archives of Bone and Joint Surgery
Volume 14, Issue 10
October 2026
Pages 649-655

  • Receive Date 19 December 2025
  • Revise Date 20 May 2026
  • Accept Date 13 May 2026